Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Population immunity to polioviruses in the context of a large-scale wild poliovirus type 1 outbreak in Tajikistan, 2010.

Khetsuriani N, Pallansch MA, Jabirov S, Saparova N, Oberste MS, Wannemuehler K, Ursu P, Wassilak S, Martin R.

Vaccine. 2013 Oct 1;31(42):4911-6. doi: 10.1016/j.vaccine.2013.06.106.

PMID:
23891502
2.

Poliovirus immunity among pregnant females aged 15-44 years, Namibia, 2010.

Cardemil CV, Jonas A, Gerber S, Weldon WC 3rd, Oberste MS, Beukes A, Sawadogo S, Patel SV, Zeko S, Muroua C, Gaeb E, Wannemuehler K, Goodson JL.

J Infect Dis. 2014 Nov 1;210 Suppl 1:S136-42. doi: 10.1093/infdis/jiu086.

3.

Deficiency of immunity to poliovirus type 3: a lurking danger?

Reinheimer C, Friedrichs I, Rabenau HF, Doerr HW.

BMC Infect Dis. 2012 Jan 26;12:24. doi: 10.1186/1471-2334-12-24.

4.

A national cross-sectional study for poliovirus seroprevalence in the Republic of Korea in 2012: implication for deficiency in immunity to polio among middle-aged people.

Kim HJ, Hwang S, Lee S, Kwon Y, Park K, Park YJ, Bae GR, Lee SW, Jeong YS, Hyeon JY.

BMC Infect Dis. 2015 Mar 28;15:164. doi: 10.1186/s12879-015-0894-z.

5.

Seroepidemiology of diphtheria and tetanus among children and young adults in Tajikistan: nationwide population-based survey, 2010.

Khetsuriani N, Zakikhany K, Jabirov S, Saparova N, Ursu P, Wannemuehler K, Wassilak S, Efstratiou A, Martin R.

Vaccine. 2013 Oct 1;31(42):4917-22. doi: 10.1016/j.vaccine.2013.07.015.

PMID:
23859842
6.

A study evaluating poliovirus antibodies and risk factors associated with polio seropositivity in low socioeconomic areas of Pakistan.

Habib M, Soofi S, Ali N, Sutter RW, Palansch M, Qureshi H, Akhtar T, Molodecky NA, Okayasu H, Bhutta ZA.

Vaccine. 2013 Apr 8;31(15):1987-93. doi: 10.1016/j.vaccine.2013.02.003.

PMID:
23429005
7.

The potential impact of expanding target age groups for polio immunization campaigns.

Duintjer Tebbens RJ, Kalkowska DA, Wassilak SG, Pallansch MA, Cochi SL, Thompson KM.

BMC Infect Dis. 2014 Jan 29;14:45. doi: 10.1186/1471-2334-14-45.

8.

Survey of poliovirus antibodies during the final stage of polio eradication in Egypt.

El-Sayed N, Al-Jorf S, Hennessey KA, Salama M, Watkins MA, Abdelwahab JA, Pallansch MA, Gary H, Wahdan MH, Sutter RW.

Vaccine. 2007 Jun 28;25(27):5062-70.

PMID:
17543428
9.

Seroprevalence of poliovirus antibodies amongst children in Zaria, Northern Nigeria.

Giwa FJ, Olayinka AT, Ogunshola FT.

Vaccine. 2012 Nov 6;30(48):6759-65. doi: 10.1016/j.vaccine.2012.09.023.

PMID:
23000220
10.

Population immunity to polioviruses among preschool children from four urban underserved low income communities, United States, 1997-2001.

Prevots DR, Pascual FB, Angellili ML, Brayden R, Irigoyen M, Larussa P, Sawyer M, Baughman AL, Pallansch MA.

Pediatr Infect Dis J. 2004 Dec;23(12):1130-6.

PMID:
15626951
11.

Factors contributing to outbreaks of wild poliovirus type 1 infection involving persons aged ≥15 years in the Democratic Republic of the Congo, 2010-2011, informed by a pre-outbreak poliovirus immunity assessment.

Alleman MM, Wannemuehler KA, Weldon WC, Kabuayi JP, Ekofo F, Edidi S, Mulumba A, Mbule A, Ntumbannji RN, Coulibaly T, Abiola N, Mpingulu M, Sidibe K, Oberste MS.

J Infect Dis. 2014 Nov 1;210 Suppl 1:S62-73. doi: 10.1093/infdis/jiu282.

12.

Is EU/EEA population protected from polio?

Nijsten D, Carrillo-Santisteve P, Miglietta A, Ruitenberg J, Lopalco PL.

Hum Vaccin Immunother. 2015;11(9):2123-31. doi: 10.1080/21645515.2015.1016673. Review.

13.

Immunogenicity of poliovirus vaccines in chronically malnourished infants: a randomized controlled trial in Pakistan.

Saleem AF, Mach O, Quadri F, Khan A, Bhatti Z, Rehman NU, Zaidi S, Weldon WC, Oberste SM, Salama M, Sutter RW, Zaidi AK.

Vaccine. 2015 Jun 4;33(24):2757-63. doi: 10.1016/j.vaccine.2015.04.055.

14.

Achieving high seroprevalence against polioviruses in Sri Lanka--results from a serological survey, 2014.

Gamage D, Palihawadana P, Mach O, Weldon WC, Oberste SM, Sutter RW.

J Epidemiol Glob Health. 2015 Dec;5(4 Suppl 1):S67-71. doi: 10.1016/j.jegh.2015.06.004.

15.

Immunity against poliomyelitis in the Netherlands, assessed in 2006 to 2007: the importance of completing a vaccination series.

van der Maas NA, Mollema L, Berbers GA, van Rooijen DM, van der Avoort HG, Conyn-Van Spaendonck MA, de Melker HE, van der Klis FR.

Euro Surveill. 2014 Feb 20;19(7):20705.

16.

The 2010 outbreak of poliomyelitis in Tajikistan: epidemiology and lessons learnt.

Yakovenko ML, Gmyl AP, Ivanova OE, Eremeeva TP, Ivanov AP, Prostova MA, Baykova OY, Isaeva OV, Lipskaya GY, Shakaryan AK, Kew OM, Deshpande JM, Agol VI.

Euro Surveill. 2014 Feb 20;19(7):20706.

17.

Poliovirus circulation among schoolchildren during the early phase of the 1992-1993 poliomyelitis outbreak in The Netherlands.

Oostvogel PM, Rumke HC, Conyn-Van Spaendonck MA, van der Avoort HG, Leeuwenburg J, van Loon AM.

J Infect Dis. 2001 Dec 1;184(11):1451-5.

18.

Seroprevalence of poliovirus antibodies among 7-month-old infants after 4 doses of oral polio vaccine in Sistan-va-Baluchestan, Islamic Republic of Iran.

Izadi S, Shahmahmoodi S, Zahraei SM, Dorostkar F, Majdzadeh SR.

East Mediterr Health J. 2015 Apr 2;21(2):83-9.

PMID:
25876819
19.

Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies.

Mas Lago P, Ramon Bravo J, Andrus JK, Comellas MM, Galindo MA, de Quadros CA, Bell E.

Bull World Health Organ. 1994;72(2):221-5.

20.

Seroprevalence of poliovirus antibodies among children in a Dominican community--Puerto Rico, 2002.

Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2005 Jun 17;54(23):580-1. Erratum in: MMWR Morb Mortal Wkly Rep. 2005 Jun 24;54(24):608..

Items per page

Supplemental Content

Support Center